Genprex up as safety panel approves dose escalation in lung cancer study

Genprex

15/08/2022 12:53

** Gene therapy co Genprex's  GNPX.O  shares rise ~5% to
$1.86 premarket
    ** Safety Review Committee approves continuation of
early-stage trial testing co's drug candidate, REQORSA, in
combination with AstraZeneca's  AZN.L  Tagrisso for treating
late-stage non-small cell lung cancer (https://refini.tv/3zPOuy0)
    ** Decision followed review of first cohort of patients in
the Phase 1 portion of trial
    ** Panel has approved advancing trial to higher dose in
second cohort of patients - GNPX
    ** Stock was up about 35% YTD as of last close


 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com;))